Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

This Assay Altered Treatment in Patients with BC

JAMA Oncol; ePub 2017 Oct 26; Tsai, Lo, et al

Publish date:

The 70-gene signature assay (70-GS) provided useful information about patients with breast cancer classified as intermediate risk by the 21-gene assay (GA), according to a study involving 840 individuals. It tended to result in treatment changes. The 70-GS was used on participants with early stage breast cancer and a 21-GA recurrence score between 18 and 30. Investigators looked at treatment changes after receiving the 70-GS result. Among the findings:

  • A significant change in adjuvant treatment was linked with receiving the 70-GS classifications overall.
  • Chemotherapy was removed from 3 in every 10 low-risk patients.
  • 37% of high-risk patients had chemotherapy added.
  • 88% of high-risk patients were recommended to receive adjuvant chemotherapy.
  • 91% of low-risk patients were recommended no chemotherapy.
  • Physicians reported being more confident in their treatment recommendations in 8 of every 10 cases.

Citation:

Tsai M, Lo S, Audeh W, et al. Association of 70-gene signature assay findings with physicians’ treatment guidance for patients with early breast cancer classified as intermediate risk by the 21-gene assay. [Published online ahead of print October 26, 2017]. JAMA Oncol. doi:10.1001/jamaoncol.2017.3470.

This Week's Must Reads

Must Reads in Breast Cancer

Stereotactic Radiotherapy System Approved For BC, FDA news release; 2017 Dec 22

Perjeta Approved for Certain Type of Early BC, Genentech news release; 2017 Dec 20

Cochrane on Bisphosphonates for Breast Cancer, Cochrane; 2017 Oct 30; O'Carrigan, Wong, et al